Indaptus Therapeutics, INC

Indaptus Therapeutics has entered into a definitive agreement to raise $12 million through the sale of 20 million shares of common stock to non-U.S. accredited investors.

Indaptus Therapeutics reports the resignation of two directors and the transition of its Chief Operating Officer to a consulting role.

Indaptus Therapeutics reported first quarter 2026 financial results, highlighting reduced operating expenses but a significant increase in net cash used in operating activities, alongside a strategic review of its development programs.

Indaptus Therapeutics has appointed Tim Ruan and Johnny Fox Arrowsmith to its Board of Directors while announcing the resignation of Matthew McMurdo.

Indaptus Therapeutics, Inc. announced the appointment of two new independent directors, Tim Ruan and Dr. Yi Zhang, effective April 22, 2026, and the resignation of Matthew McMurdo.

Indaptus Therapeutics, Inc. has announced the resignation of its CFO, Nir Sassi, and the appointment of Qinglai Lu to its Board of Directors and Yu Ding as the new CFO.

Indaptus Therapeutics reports a significant decrease in R&D expenses and a net loss for Q1 2026, while exploring strategic transaction opportunities.

Indaptus Therapeutics reported an increased net loss for the nine months ended September 30, 2025, while advancing its Decoy20 clinical trials and raising significant capital to extend its cash runway into the first quarter of 2026.

Indaptus Therapeutics reports increased net losses and significant cash burn, raising substantial doubt about its ability to continue as a going concern, despite advancing its Decoy20 clinical program.

Indaptus Therapeutics announces its Q1 2025 financial results, detailing progress in its Phase 1 clinical trial for Decoy20 and the initiation of a combination study with Tislelizumab.

Indaptus Therapeutics reported its Q3 2024 financial results, highlighting ongoing clinical trials and a new collaboration, but also expressing substantial doubt about its ability to continue as a going concern.

Indaptus Therapeutics reports a net loss of $7.8 million for the first half of 2024, while progressing its Phase 1 clinical trial for Decoy20.

Indaptus Therapeutics, a clinical-stage biotechnology company, released its 2024 financial results and provided an update on its ongoing clinical development programs, including the Phase 1 trial of Decoy20 and a planned combination study with BeiGene's tislelizumab.

Indaptus Therapeutics, a clinical-stage biotech company, released its 2023 annual report, detailing financial results and progress in its Phase 1 clinical trial for Decoy20.

Indaptus Therapeutics Director David E. Lazar sold a substantial portion of his Series AA and Series AAA Preferred Stock holdings, convertible into millions of common shares.

Indaptus Therapeutics Director Jerome Jabbour was granted 25,000 stock options as part of the company's non-employee director compensation program.

Indaptus Therapeutics Director Avraham Ben-Tzvi acquired 25,000 shares of restricted common stock and 25,000 stock options as part of compensation.

Indaptus Therapeutics Director David Natan was granted options to purchase 25,000 shares of common stock as part of the company's non-employee director compensation program.

Indaptus Therapeutics' Chief Financial Officer, Nir Sassi, acquired 26,758 shares of common stock at $2.03 per share on December 22, 2025, as part of an employment agreement amendment.

Indaptus Therapeutics Co-Chief Executive Officer Jeffrey Meckler acquired 216,617 shares of common stock at $2.03 per share, increasing his total beneficial ownership to 229,929 shares.

Indaptus Therapeutics, Inc. has scheduled its 2026 Annual Meeting of Stockholders for August 10, 2026, to be held virtually, with key proposals including director elections and the approval of a new equity incentive plan.

Indaptus Therapeutics calls a Special Meeting to approve a significant capital raise, board changes, and corporate governance amendments crucial for its future strategic direction and Nasdaq compliance.

Indaptus Therapeutics, Inc. is convening a Special Meeting of Stockholders on July 25, 2025, to seek approval for the issuance of common stock underlying convertible notes and warrants from a recently closed and ongoing private placement, including participation by its CEO, to comply with Nasdaq listing rules.

Indaptus Therapeutics, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.

Indaptus Therapeutics is holding its annual meeting on June 10, 2025, to vote on director elections, auditor ratification, executive compensation, and a potential reverse stock split.

Indaptus Therapeutics, Inc. files a definitive proxy statement with the SEC.

Indaptus Therapeutics filed an S-1/A to include a new engagement agreement with H.C. Wainwright & Co., detailing multiple recent capital raises totaling over $7 million.

Indaptus Therapeutics, a clinical biotechnology company, filed an S-1 registration statement for a best-efforts public offering of common stock and warrants to raise up to $15 million for R&D and general corporate purposes.

Indaptus Therapeutics registers for the resale of up to 10 million shares of common stock by YA II PN, LTD., potentially raising up to $20 million through a standby equity purchase agreement.

Indaptus Therapeutics is registering for the resale of up to 1,941,229 shares of common stock by selling stockholders, primarily related to warrants issued in recent private placements.

Indaptus Therapeutics is registering for the resale of 1,643,837 shares of common stock issuable upon the exercise of warrants from a recent private placement.

Sino Lion Ventures Limited and Chenhao Xu filed an amendment to their Schedule 13D regarding their 29.19% stake in Indaptus Therapeutics, Inc.

Junyi Dai reports a change in his beneficial ownership percentage of Indaptus Therapeutics due to an increase in the company's total outstanding shares.

Ting Yang filed an amendment to his Schedule 13D disclosing an 8.44% beneficial ownership stake in Indaptus Therapeutics, Inc. following a dilution event.

Yun Yao discloses a 31.51% beneficial ownership stake in Indaptus Therapeutics, Inc. following a dilution event.

Several significant shareholders in Indaptus Therapeutics have formally disbanded their reporting group, with one shareholder falling below the 5% ownership threshold.

A group of investors led by Yun Yao acquired a controlling stake in Indaptus Therapeutics, leading to a significant change in beneficial ownership and the appointment of a new CEO.

Multiple entities and individuals associated with Yorkville Advisors have filed a Schedule 13G amendment for Indaptus Therapeutics, reporting zero shares beneficially owned.

Multiple entities affiliated with Yorkville Advisors Global, including YA II PN, Ltd., have disclosed a 9.99% beneficial ownership stake in Indaptus Therapeutics, Inc., stemming from a Standby Equity Purchase Agreement.